VigRX Plus passed its clinical trials with flying colors. Learn all about the results that the majority of the guys all gained from taking this supplement.

With the accumulated pre-clinical data, VigRx Plus has shown promise as a novel agent for the management of ED. It was also imperative to test its safety and effectiveness in humans.

The clinical research was conducted by Verdic Lifesciences Pvt. Uh, Ltd.

It was a triple-blind study, which indicates that no one interested in assessing the findings (doctors, analysts, etc.) understood if the subjects were taking VigRX Plus® or placebo.

The experiment lasted 84 days, with evaluation visits taking place on Day 28, Day 56 and Day 84.

The findings were measured using the IIEF – the International Erectile Function Index. This appraisal method is widely respected in the international community and has shown robust care responsiveness in trials in the United States, Europe and Asia. Measures:

Frequency of erection
Firmness of erection
Frequency of the Penetration Partner
Frequency of maintenance of erection after penetration
Capacity to sustain an erection for completion

VigRX Supplement Clinical Research and Testing Results

Brought to you by VigRX Official Store

Results From Other Clinical Trials For VigRX Plus

Evidence is lacking for multi-ingredient herbal supplements claiming therapeutic effect in sexual dysfunction in men. We examined the safety and efficacy of VigRX Plus (VXP) a proprietary polyherbal preparation
for improving male sexual function, in a double blind, randomized placebo-controlled, parallel groups, multi-centre study.
 
Methods: 78 men aged 2550 years of age; suffering from mild to moderate erectile dysfunction (ED), participated in this study. Subjects were randomized to receive VXP or placebo at a dose of two capsules twice daily for 12 weeks. The international index of erectile function (IIEF) was the primary outcome measure of efficacy.
 
Other efficacy measures were: Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS), Serum testosterone, Semen analysis, Investigators Global assessment and Subjectsopinion.
 
Results: In subjects receiving VXP, the IIEF-Erectile Function (EF) scores improved significantly as compared to placebo. After 12 weeks of treatment, the mean (sd) IIEF-EF score at baseline increased from 16.08 (2.87) to 25.08 (4.56) in the VXP group versus 15.86 (3.24) to 16.47 (4.25) in the placebo group (P < 0.0001). Similar results were observed in each of the remaining four domains of the IIEF (orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction).
 
There was a significant difference for VXP versus placebo comparison of mean (sd) EDITS scores of patients: 82.31(20.23) vs 36.78(22.53) and partners :(82.75(9.8) vs 18.50(9.44);P< 0.001. Thirty-five out of 39 (90%) subjects from the VXP group and one (3%) from the placebo group wished to continue with the treatment they received. Investigators global assessment rated VXP therapy as very good to excellent in more than 50% patients and placebo therapy as fair to good in about 25% of patients. Incidence of side effects and subjects rating for tolerability of treatment was similar in both groups.
 
Conclusions: VigRX Plus was well tolerated and more effective than placebo in improving sexual function in men.
 
Trial Registration: Clinical Trial Registry India, CTRI/2009/091/000099, 31-03-2009

Citations and Abstract

Shah, Gaurang & Patankar, Suresh & Pensalwar, Shrikant & Sabale, Vilas & Sonawane, Navneet. (2012). Evaluation of a multi-herb supplement for erectile dysfunction: a randomized double-blind, placebo-controlled study. BMC complementary and alternative medicine. 12. 155. 10.1186/1472-6882-12-155. Background:
Evidence is lacking for multi-ingredient herbal supplements claiming therapeutic effect in sexual dysfunction in men. We examined the safety and efficacy of VigRX Plus (VXP) – a proprietary polyherbal preparation for improving male sexual function, in a double blind, randomized placebo-controlled, parallel groups, multi-centre study.

Methods:
78 men aged 25-50 years of age; suffering from mild to moderate erectile dysfunction (ED), participated in this study. Subjects were randomized to receive VXP or placebo at a dose of two capsules twice daily for 12 weeks. The international index of erectile function (IIEF) was the primary outcome measure of efficacy. Other efficacy measures were: Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS), Serum testosterone, Semen analysis, Investigator’s Global assessment and Subjects’ opinion.

Results:
In subjects receiving VXP, the IIEF-Erectile Function (EF) scores improved significantly as compared to placebo. After 12 weeks of treatment, the mean (sd) IIEF-EF score at baseline increased from 16.08 (2.87) to 25.08 (4.56) in the VXP group versus 15.86 (3.24) to 16.47 (4.25) in the placebo group (P < 0.0001). Similar results were observed in each of the remaining four domains of the IIEF (orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction).There was a significant difference for VXP versus placebo comparison of mean (sd) EDITS scores of patients: 82.31(20.23) vs 36.78(22.53) and partners :(82.75(9.8) vs 18.50(9.44);P < 0.001. Thirty-five out of 39 (90%) subjects from the VXP group and one (3%) from the placebo group wished to continue with the treatment they received. Investigator’s global assessment rated VXP therapy as very good to excellent in more than 50% patients and placebo therapy as fair to good in about 25% of patients. Incidence of side effects and subject’s rating for tolerability of treatment was similar in both groups.

Conclusions:
VigRX Plus was well tolerated and more effective than placebo in improving sexual function in men.

Trial registration:
Clinical Trial Registry India, CTRI/2009/091/000099, 31-03-2009.

Shah, Gaurang & Patankar, Suresh & Pensalwar, Shrikant & Sabale, Vilas & Sonawane, Navneet. (2012). Evaluation of a multi-herb supplement for erectile dysfunction: a randomized double-blind, placebo-controlled study. BMC complementary and alternative medicine. 12. 155. 10.1186/1472-6882-12-155. e study.

There weren’t any serious negative side effects reported with VigRX Plus use at all.